SECsense Logo

Oncolytics Biotech Inc. Form 6-K Report: February 2025 Insights

$ONCY
Form 6-K
Filed on: 2025-02-18
Source
Oncolytics Biotech Inc. Form 6-K Report: February 2025 Insights

Based on the provided section of the financial report (Form 6-K) for Oncolytics Biotech Inc., here are the key pieces of information extracted:

  1. Company Information:
  • Name: Oncolytics Biotech Inc.
  • Location: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
  • Commission File Number: 001-38512.
  1. Filing Details:
  • Type of Filing: Form 6-K
  • Filing Date: February 18, 2025.
  • Reporting Period: Month of February 2025.
  1. Regulatory Compliance:
  • This report is filed in accordance with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, which pertains to foreign private issuers.
  1. Submission Method:
  • The document indicates compliance with Regulation S-T, specifically regarding the submission of Form 6-K in paper form under certain conditions.
  1. Signature:
  • The report was signed by Kirk Look, who serves as the Chief Financial Officer of Oncolytics Biotech Inc.
  1. Exhibits:
  • An exhibit (99.1) is included, referenced as a "Press Release," which may contain additional important information.
  1. Notes:
  • There are notes regarding the conditions under which the Form 6-K can be submitted in paper format, emphasizing the need for compliance with specific regulatory requirements.

Insights:

  • The filing indicates that Oncolytics Biotech Inc. is actively maintaining its compliance with SEC reporting requirements as a foreign private issuer.
  • The presence of a press release suggests that there may be significant updates or developments regarding the company that could impact stakeholders and market perception.
  • The report serves as a formal communication channel to keep investors informed about the company's operational status and any material events that occurred during the reporting period.

This summary captures the essential details and implications of the filing, emphasizing the company's regulatory adherence and the potential significance of the included press release.